NZ601348A - Methods for predicting response of triple-negative breast cancer to therapy - Google Patents

Methods for predicting response of triple-negative breast cancer to therapy

Info

Publication number
NZ601348A
NZ601348A NZ601348A NZ60134811A NZ601348A NZ 601348 A NZ601348 A NZ 601348A NZ 601348 A NZ601348 A NZ 601348A NZ 60134811 A NZ60134811 A NZ 60134811A NZ 601348 A NZ601348 A NZ 601348A
Authority
NZ
New Zealand
Prior art keywords
triple
therapy
negative breast
vegfr2
methods
Prior art date
Application number
NZ601348A
Other languages
English (en)
Inventor
Xinjun Liu
Phillip Kim
Richard Kirkland
Tani Lee
Belen Ybarrondo
Sharat Singh
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of NZ601348A publication Critical patent/NZ601348A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ601348A 2010-01-12 2011-01-12 Methods for predicting response of triple-negative breast cancer to therapy NZ601348A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29443310P 2010-01-12 2010-01-12
US32562410P 2010-04-19 2010-04-19
US32860210P 2010-04-27 2010-04-27
US35183810P 2010-06-04 2010-06-04
PCT/US2011/021026 WO2011088149A2 (en) 2010-01-12 2011-01-12 Methods for predicting response of triple-negative breast cancer to therapy

Publications (1)

Publication Number Publication Date
NZ601348A true NZ601348A (en) 2014-07-25

Family

ID=44304951

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601348A NZ601348A (en) 2010-01-12 2011-01-12 Methods for predicting response of triple-negative breast cancer to therapy

Country Status (15)

Country Link
US (2) US9488654B2 (https=)
EP (1) EP2524232B1 (https=)
JP (1) JP5764144B2 (https=)
KR (1) KR20120115390A (https=)
CN (1) CN102822676B (https=)
AU (1) AU2011205343B2 (https=)
BR (1) BR112012017084A2 (https=)
CA (1) CA2787225A1 (https=)
ES (1) ES2505466T3 (https=)
IL (1) IL220833A0 (https=)
MX (1) MX2012008153A (https=)
NZ (1) NZ601348A (https=)
RU (1) RU2558931C2 (https=)
WO (1) WO2011088149A2 (https=)
ZA (1) ZA201206019B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
EP2788752B1 (en) * 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
KR20140114415A (ko) * 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
RU2015102026A (ru) * 2012-06-26 2016-08-10 Ф.Хоффманн-Ля Рош Аг Биомаркеры в плазме крови для комбинированных терапий с использованием бевацизумаба при лечении рака молочной железы
US9422602B2 (en) 2012-08-15 2016-08-23 Bio-Rad Laboratories, Inc. Methods and compositions for determining nucleic acid degradation
WO2014071218A2 (en) * 2012-11-02 2014-05-08 University Of Utah Research Foundation Biomarkers for breast cancer and methods of using same
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
WO2015028974A2 (en) * 2013-08-30 2015-03-05 Nestec S.A. Polyp recurrence
WO2015095404A2 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
EP3006940A1 (en) * 2014-10-10 2016-04-13 Ruprecht-Karls-Universität Heidelberg Biomarkers for predicting the response to anti-angiogenic cancer therapy
CN105891496A (zh) * 2014-12-09 2016-08-24 上海华盈生物医药科技有限公司 酪氨酸激酶抑制剂类靶向用药指导抗体芯片和检测方法
CN104830775B (zh) * 2015-04-14 2019-06-21 上海中医药大学附属龙华医院 一种三阴性乳腺癌顺铂耐药细胞株及其制备方法和用途
JP6896650B2 (ja) 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
WO2016209926A1 (en) * 2015-06-22 2016-12-29 Thomas Jefferson University Cancers expressing ccr5 and methods of treatment of same
US10724071B2 (en) 2015-10-14 2020-07-28 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used
RU2616533C1 (ru) * 2016-03-15 2017-04-17 Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) Способ прогнозирования эффективности терапии эверолимусом у больных метастатическим раком почки
IL245861A0 (en) 2016-05-25 2016-09-04 Yeda Res & Dev Use of substances to treat drug-resistant tumors
CN109789204A (zh) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 基于her2和her3通路亚型选择乳癌患者药物疗法的方法
CN106645728A (zh) * 2016-11-09 2017-05-10 百奥森（江苏）食品安全科技有限公司 一种食品中氟喹诺酮类药物的检测试剂盒
RU2648523C1 (ru) * 2017-05-22 2018-03-26 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию
CN109470854B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌诊断用蛋白芯片及试剂盒
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
US20210088523A1 (en) * 2019-09-23 2021-03-25 Sri International Methods for detecting circulating tumor cells in non-small cell lung cancer
US11366101B1 (en) 2020-12-31 2022-06-21 Elephas Biosciences Corporation Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue
WO2024187968A1 (zh) * 2023-03-15 2024-09-19 侯明宏 用于治疗三阴性乳癌的药物组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6897073B2 (en) 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
EP1307285A2 (en) 2000-08-03 2003-05-07 Massachusetts Institute Of Technology Microarrays of functional biomolecules, and uses therefor
AU2002303384A1 (en) 2001-04-17 2002-10-28 William J. Dower Epitope-captured antibody display
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
US20060263837A1 (en) 2004-06-17 2006-11-23 Liu George D Immunoassay system and method for detection of antigens
SI1853250T1 (sl) * 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
DK2064549T3 (da) * 2006-09-21 2013-02-04 Nestec Sa Antistof-baserede arrays til detektion af flere signaltransducere i sjældne cirkulerende celler
RU2341198C2 (ru) * 2006-11-27 2008-12-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ оценки ангиогенных факторов при химиотерапии рака молочной железы
EP2109686A2 (en) * 2007-01-18 2009-10-21 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
JP2010540459A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US8071315B2 (en) * 2008-04-30 2011-12-06 Sanford-Burnham Medical Research Institute Detecting Bcl-B expression in cancer and uses thereof
JP5718319B2 (ja) 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
AU2011281706A1 (en) * 2010-07-19 2013-01-10 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Also Published As

Publication number Publication date
AU2011205343B2 (en) 2015-08-13
EP2524232A2 (en) 2012-11-21
WO2011088149A3 (en) 2011-10-27
WO2011088149A2 (en) 2011-07-21
US20130012407A1 (en) 2013-01-10
ES2505466T3 (es) 2014-10-10
RU2012134390A (ru) 2014-02-20
EP2524232A4 (en) 2013-06-12
MX2012008153A (es) 2012-11-06
US9488654B2 (en) 2016-11-08
CA2787225A1 (en) 2011-07-21
IL220833A0 (en) 2012-08-30
US10697967B2 (en) 2020-06-30
EP2524232B1 (en) 2014-08-06
KR20120115390A (ko) 2012-10-17
JP5764144B2 (ja) 2015-08-12
BR112012017084A2 (pt) 2016-04-12
RU2558931C2 (ru) 2015-08-10
CN102822676B (zh) 2015-02-18
ZA201206019B (en) 2015-06-24
HK1178602A1 (en) 2013-09-13
JP2013517461A (ja) 2013-05-16
US20170227542A1 (en) 2017-08-10
AU2011205343A1 (en) 2012-08-02
CN102822676A (zh) 2012-12-12

Similar Documents

Publication Publication Date Title
NZ601348A (en) Methods for predicting response of triple-negative breast cancer to therapy
NZ631197A (en) Anti sez6 antibodies and methods of use
MX2015018051A (es) Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
GB2531881A (en) Method of isolating circulating tumor cells
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
BR112013008480A2 (pt) anticorpos contra tumor e usos específicos dos mesmos
WO2014018563A3 (en) Methods for the treatment of cancer
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
UA117121C2 (uk) Біспецифічне антитіло до egfr/с-мет
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
HK1213946A1 (zh) 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
GEP20176805B (en) Conjugated antibodies against ly75 for the treatment of cancer
HK1197273A1 (en) Methods and materials related to ovarian cancer
WO2013019945A3 (en) Method for selection of chemotherapeutic agents for adenocarcinoma cancer
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
MX2014010713A (es) Activacion de procaspasa 3 mediante terapia de combinacion.
WO2014151606A3 (en) Methods of treating pancreatic cancer
NZ712023A (en) Caix stratification based cancer treatment
GB201207722D0 (en) Method
WO2012019125A3 (en) Biomarkers for prostate cancer and methods for their detection
WO2012118969A3 (en) Method of selecting cancer patients for anti-angiogenesis therapy in combination with chemotherapy
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли
RU2012147673A (ru) Способ прогнозирования исхода мышечно-инвазивного рака мочевого пузыря после комбинированного лечения
MX2014014829A (es) Anticuerpos autoinmunes.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2016 BY CPA GLOBAL

Effective date: 20150103

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2017 BY CPA GLOBAL

Effective date: 20151231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2018 BY CPA GLOBAL

Effective date: 20161203

LAPS Patent lapsed